Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward

LONG-LASTING VEGF BLOCKERS, COMPOUNDS WITH VEGF- INDEPENDENT MECHANISM AND, TOPICAL AND ORAL TREATMENT OPTIONS, BRING THE QUEST FOR THE “IDEAL RETINAL DRUG” A STEP NEARER Multifactorial nature of DME led a definite role of steroids in the current treatment paradigm; development of new route of administration of steroids to enhance clinical efficacy with better safety underway The late stage pipeline comprises of long-lasting VEGF blockers and compounds with VEGF-independent mechanisms such asTie-2/Angiopoietin pathway modulators and integrin inhibitorsNon-invasive therapies, prophylactic alternatives…

Continue Reading

BioSpectrum Article – Face-lifting biopharma industry image

Covid-19 pandemic gives an opportunity for the BioPharma industry to transform its image. Can the initiatives and learnings from Covid-19 be applied to other critical therapy areas?  Can the time and cost of development be significantly reduced such that the pharma companies can launch the products at affordable prices to ensure that every patient gets access to the medicines? Emerging markets are gaining more importance than ever, led by China, considering the scales of volumes they offer. With time and…

Continue Reading

5 pitfalls AI healthcare start-ups need to avoid

Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-ups. Pharma and healthcare are data-rich industries and AI helps by turning data into actionable insights, allowing us to solve complex, intricate problems. Using machine learning, AI algorithms can generate patterns that will enable us to predict toxicity, find potential combination treatments, identify and predict new drugs and expand usage…

Continue Reading

Mehta Analysis: The Promise Of 2021

Executive Summary Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Between January and early April 2020, over 80 COVID-19-focused programs entered the clinic, seven of which are vaccines. Such advances would normally take 5-10 times longer. Here we focus on two exciting and complementary opportunities. The first is the chance to help society gain a realistic understanding of how an R&D-anchored drug reaches their…

Continue Reading

How AI is fighting COVID-19: the companies using intelligent tech to find new drugs

The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth. We highlight the companies that are using AI to develop treatments that could end the outbreak. Pharma is facing a race against time to tackle the exponential rise of COVID-19 cases, and as a result there has been an unprecedented level of data sharing and cooperation in…

Continue Reading

Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally

But Are Industry Leaders Keeping Pace? Executive Summary: Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC. Biopharma business is fundamentally changing, but is the leadership keeping pace? The US Business Roundtable last August redefined the purpose of…

Continue Reading

Japan Biosimilars: Landscape Today, Outlook Tomorrow – ‘Biosame’ entry, uninterrupted supply and companies’ strong front-end footprint requirements make it a distinct market

- After a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS- Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constantsupply need, Japanese CDMO imminent to seal  this local need Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and…

Continue Reading

MP Group – Global Biosimilars Outlook, 2019

Year 2019 has been a pivotal year for biosimilars and it is our pleasure to share with you the Global Biosimilars Outlook, 2019, whichcovers in-depth analyses of biosimilars landscape across major geographies (EU, US, Japan, China and India) and presents ideas on how to move ahead in order to achieve global leadership in what we believe will be $40B market by 2025. EU Biosimilar Landscape: The most evolved market currently at a tipping point A matured biosimilar market, although with heterogeneous penetration across the member statesBetter prescriber incentives and multiple winning tenders will not…

Continue Reading

Mehta Analysis: Who Will Speak Out As Regulators Are Politicized? FDA leadership Moves, China-US Trade Spat And Brexit Threaten Sector

In his latest opinion piece, Viren Mehta fears the impact that ideologically motivated and protectionist actions around the world will have on the biopharma sector and ultimately on patients. In this new era when politicians seem able to fool some significant number of people all the time, the safety valve of the civil service apparatus is more readily throttled. This came into full view as the autumn colors were fading in late October in Washington. In this new era when…

Continue Reading

MP Group – Biosimilars Landscape – China and India

As you are exploring biosimilar opportunities, we would be delighted to share our insights to help you advance your strategy. Our active work has enabled us to develop an in depth understanding of the global biosimilar opportunity, and many of our forecasts of the past decade are now being realized. In fact, that is why the title of the attached slide deck is “Creating a global biosimilars leadership - Combining complementary strengths of China and India” (Click here to download) Global…

Continue Reading
Close Menu